Conditions: CML Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
Keywords: Philadelphia chromosome positive Ph+ chronic myelogenous leukemia chronic phase CML-CP low imatinib trough levels
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 3
Healthy volunteers: no

Brief summary:
This study is to determine the number of European Leukemia Network (ELN)guideline defined treatment failure events from time of study entry in CML-CP patients with low imatinib trough concentrations treated with nilotinib.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: nilotinib
Intervention descriptions: intervention 1: All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours

Protocol document: